there is nothing sinister about ProSavin being trialled in France, Oxford Biomedica (inventors of Prosavin and an offshoot of Oxford University), are very close to a big French pharma group called Sanofi-aventis, hence there are all sorts of commercial advantages to hosting the trials in France.

Considering the global reputation of Oxford University (ranked anywhere from 2nd to 10th in the world university league tables), and the track record of the French with PD research, (remember they pioneered DBS), if I lived in the US I would want to know why the FDA was introducing more delay for potential treatments purely because they hadn't been trialled in the US. Perhaps they are afraid of litigation, who knows, if the French tell me Prosavin works then my waiver of liability will be signed in seconds.

Take care,
Neil.